Diagnostics & Informatics
The current state
as ofDiagnostics & Informatics in 2026 is shifting from standalone tests, instruments, and departmental software toward integrated, workflow-embedded platforms that connect diagnostics, imaging, pathology, genomics, and patient data. Strategic advantage is increasingly determined by interoperability, reimbursement, regulatory execution, cloud architecture, and the ability to turn diagnostic outputs into actionable clinical and operational decisions.
What’s shaping Diagnostics & Informatics right now
- EU IVDR, FDA software oversight, and privacy rules are raising compliance costs and making regulatory execution a core market-access advantage for diagnostics vendors.
- Chronic disease, aging populations, and oncology biomarker use are increasing demand for repeated, longitudinal, and personalized diagnostic decision-making across care settings.
- Labor shortages and reimbursement pressure are forcing laboratories and health systems to prioritize automation, throughput, and total cost per reportable result over instrument features alone.
- Decentralized care is moving testing into homes, pharmacies, and near-patient settings, making connectivity, sample logistics, and care-pathway integration as important as assay accuracy.
- Geopolitical and supply-chain fragility in reagents, plastics, semiconductors, and specialized manufacturing is favoring scale, regionalization, and vertically resilient operating models.
Dynamics on the rise and in decline
Rising
Platform consolidation
Large diagnostics and imaging vendors are acquiring digital pathology, AI, and informatics assets to capture a greater share of the end-to-end diagnostic workflow.
Shift to recurring cloud services
The model is moving away from upfront capital equipment and perpetual licenses toward recurring reagent pull-through, cloud subscriptions, managed services, and outcome-linked workflow contracts.
Stable
Bifurcating diagnostic pricing
Routine chemistry and immunoassays are pressured by scale-driven contracting, while oncology, molecular, and companion diagnostics keep premiums only when supported by reimbursement and clinical-utility evidence.
This week’s brief
Earlier briefs
View all →- Diagnostics move into care pathways, CMS resets pricing, and routing becomes the new moatOctober 26, 2026
- ctDNA Gates Therapy, AI Moves Into Workflow, and Distribution Becomes the New MoatOctober 19, 2026
- Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidatesOctober 12, 2026
- Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision supportOctober 5, 2026
- Therapy-Specific Liquid Biopsy, Routed Telepathology, and Workflow-Control AI Tighten Diagnostic ControlSeptember 28, 2026
- Access gates tighten, workflow owners win, and pathology platforms scale across bordersSeptember 21, 2026
- Workflow-embedded diagnostics win, EU access bottlenecks tighten, and biomarker evidence becomes the moatSeptember 14, 2026
- Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercializationAugust 31, 2026
- Workflow interoperability, integrated diagnostics, and embedded governance reshape AI control pointsAugust 24, 2026
- Workflow-specific AI clears first, companion diagnostics gain reimbursed access, and multiomics shifts to deploymentAugust 17, 2026
- Embedded Clinical Workflows, Commercial Validation Infrastructure, and Cloud Teleradiology OrchestrationAugust 10, 2026
- Infrastructure wins in diagnostics, AI embeds in workflows, and serial testing drives oncology revenueAugust 3, 2026
- Reimbursement and validation reshape diagnostics value, AI diagnostics enter regulated territoryJuly 27, 2026
Tracked trends
View all →- China Neurology Biomarkers — Coverage and policy are turning blood tests into routine care pathways, expanding adoption from assay validation into real-world screening and follow-up.
- At-Home HPV Routing — Clearance is no longer the finish line; diagnostics are now won through reimbursement, distribution, and repeatable site activation.
- CDx Platformization — At-home collection, broad biomarker panels, and ctDNA-guided decisions are pushing diagnostics value upstream into the earliest steps of care.
- Diagnostic AI Workflow — Diagnostic AI is maturing into embedded workflow software that automates routine analysis, clears regulators, and fits existing clinical operations.
- Distribution Control — Vendors are turning diagnostic interpretation into a governed enterprise workflow, making platforms the new battleground for adoption, data, and recurring revenue.
Deep dive
- What macro forces are shaping diagnostics and informatics in 2026?
- Diagnostics and informatics in 2026 are being shaped by the shift from centralized testing to distributed, data-driven care, with more testing moving into point-of-care, at-home, pharmacy, and remote-monitoring settings. AI is increasingly embedded in imaging, pathology, laboratory operations, and clinical decision support, with value shifting toward workflow integration, predictive analytics, and measurable efficiency gains. Healthcare cost pressure, chronic disease growth, infectious disease management, and antimicrobial resistance are increasing demand for faster, more scalable diagnostic tools. At the same time, regulation, reimbursement, cybersecurity, and geopolitical supply-chain risk are making interoperability, evidence generation, and operational resilience more important for vendors and buyers.
- What major developments reshaped diagnostics and informatics in the last 6 months?
- The biggest shift was from standalone tests and software toward integrated diagnostic workflows that combine instruments, digital pathology, imaging IT, and clinical decision support. Biomarker-linked diagnostics also became more commercially important, with oncology approvals, real-world evidence partnerships, and blood-based screening expanding the role of diagnostics in treatment selection and early detection. Digital pathology and imaging AI moved further into regulated, enterprise-scale deployment, while vendors increasingly competed on interoperability, workflow efficiency, and the ability to connect results directly to care.
- What are the main competitive dynamics in diagnostics and informatics in 2026?
- In 2026, diagnostics and informatics are shifting from standalone instruments and tests toward integrated, data-enabled platforms that combine hardware, software, services, and analytics. Consolidation is happening both among vendors and among buyers, as large health systems and reference labs use scale to negotiate lower prices, demand interoperability, and favor fewer strategic suppliers. Pricing pressure remains strong because reimbursement is tight and customers are pushing for bundled contracts, recurring consumables, and workflow efficiencies rather than premium pricing for individual tests. New entrants are most active in specialty diagnostics, molecular testing, digital pathology, and AI-driven software, while cloud adoption, automation, and regulatory digitization are changing the value chain toward more recurring software and service revenue.
- How are diagnostics and informatics changing in 2026?
- Diagnostics and informatics are shifting from standalone tests and instruments to connected, AI-assisted workflows that combine acquisition, automation, data management, interpretation, and clinical decision support. AI is being embedded across radiology, pathology, laboratory systems, and electronic health records to improve triage, detection, reporting, and predictive analytics. Digital pathology is expanding through whole-slide imaging, cloud image management, and AI-based biomarker analysis, while interoperability and data governance are becoming key competitive priorities. Cloud-native platforms and integrated software services are increasingly capturing value across the diagnostic workflow.
- Who are the leading players in diagnostics and informatics today?
- The diagnostics and informatics market is led by diversified incumbents such as Roche, Abbott, Danaher, Siemens Healthineers, GE HealthCare, Philips, Thermo Fisher Scientific, bioMérieux, Hologic, Quest Diagnostics, and Labcorp. Challengers often focus on narrower segments such as enterprise imaging, laboratory informatics, molecular diagnostics, and oncology testing, with companies like Sectra, Agfa HealthCare, LabVantage, LabWare, Guardant Health, Tempus AI, and Exact Sciences. Emerging players are concentrated in AI-assisted interpretation, digital pathology, cardiovascular imaging, at-home testing, and cloud-based workflows, including Aidoc, Viz.ai, Qure.ai, RapidAI, HeartFlow, Paige, PathAI, Ibex Medical Analytics, Lunit, Cleerly, Freenome, Healthy.io, and Butterfly Network. Overall, the market is being shaped by the shift toward integrated platforms that combine instruments, software, data, and clinical decision support.
- What developments signal major shifts in diagnostics and informatics?
- Major shifts in diagnostics and informatics are developments that change clinical workflows, regulatory access, reimbursement, data architecture, or competitive positioning. Examples include diagnostics embedded into EHR, LIS, PACS, or pathology workflows; FDA or EU regulatory milestones; reimbursement changes; and companion diagnostics tied to therapy selection. Production-grade AI, interoperability breakthroughs, and cloud-native informatics platforms can also be significant when they move from pilots into routine clinical use and alter how data is captured, shared, or acted on. By contrast, isolated feature launches, press releases, or single accuracy claims are usually routine noise unless they lead to measurable adoption or market impact.